Definition · Plain-language
Drug Supply Chain Security Act (DSCSA)
The Drug Supply Chain Security Act (DSCSA) is a 2013 US law that establishes an interoperable, electronic system to identify and trace prescription drugs as they move through the supply chain.
The step most authors miss
Doing CRediT right? Don’t stop at the statement.
A CRediT statement credits you inside one paper. The recognition CRediT was built for happens when those roles are tied to you, persistently. Sign in with your ORCID — free — and claim your CRediT contributions on casrai.org, the home of the standard. They become a verified, portable part of your identity, not a line that disappears into one PDF.
Free: claim your contributions, then export a journal-ready CRediT statement, schema.org structured data, JATS XML, CSV or BibTeX — and preview your public profile. A membership publishes that profile publicly and verifies the journals you serve.
What the DSCSA does
The Drug Supply Chain Security Act was enacted in November 2013 as Title II of the Drug Quality and Security Act. Its purpose is to enhance the security of the US pharmaceutical distribution chain by creating an interoperable, electronic system to identify and trace certain prescription drugs as they are distributed. The law is designed to make it easier to detect and remove potentially dangerous products — such as counterfeit, stolen or contaminated drugs — from the supply chain, protecting patients from harmful medicines.
Core requirements
The DSCSA introduces several building blocks. Product identification requires manufacturers and repackagers to apply a unique product identifier, including a serial number, to individual packages (serialisation). Product tracing requires trading partners to provide and capture transaction information as products change hands. Product verification establishes systems to verify product identifiers. And the authorised-trading-partner provisions require manufacturers, wholesale distributors, dispensers and repackagers to be appropriately licensed or registered. Together these support unit-level, electronic, interoperable tracing.
A phased timeline
The DSCSA was structured to be implemented over roughly a decade, with the fully interoperable, electronic, package-level tracing system targeted for late 2023. Recognising the operational complexity, the FDA announced a stabilisation period providing additional time for trading partners to reach full interoperability without exposure to enforcement action for certain requirements during that window. The phased approach reflects the scale of coordination needed across manufacturers, distributors and dispensers to make the system work end to end.
Key facts
At a glance
- Definition: US law creating an electronic system to trace prescription drugs.
- Stands for: Drug Supply Chain Security Act.
- Enacted: 2013, as Title II of the Drug Quality and Security Act.
- Key tools: Serialisation, transaction tracing, verification, trading-partner rules.
- Goal: Detect and remove counterfeit, stolen or contaminated products.
- Timeline: Phased to 2023, with an FDA stabilisation period that followed.
Common misconceptions
What people often get wrong
Often heard: The DSCSA regulates whether a drug is safe and effective.
Actually: The DSCSA governs supply-chain security and traceability — identifying and tracing products as they are distributed. Safety and effectiveness for marketing are determined separately through the NDA and BLA approval processes.
Often heard: The DSCSA only applies to drug manufacturers.
Actually: It applies across the supply chain. Manufacturers, repackagers, wholesale distributors and dispensers all have authorised-trading-partner, tracing or verification obligations under the Act.
Often heard: Full DSCSA interoperability was required immediately in 2023.
Actually: The fully interoperable electronic system was targeted for late 2023, but the FDA provided a stabilisation period giving trading partners additional time to achieve interoperability before certain requirements would be enforced.
Going deeper
